Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients

The Egyptian Journal of Otolaryngology

Table 7 Duration between covidCOVID-19 infection and start of mucormycosis

	Duration between COVID-19 infection and start of mucormycosis		Test value	p-value	Sig.
	Median (IQR)	Range	Test value	p-value	Sig.
Visual loss
No	30 (21–45)	7–90	−0.134^a	0.893	NS
Yes	30 (21–60)	14–80	−0.134^a	0.893	NS
Disturbed conscious
No	30 (25–60)	7–90	−1.892^a	0.059	NS
Yes	20 (14–21)	14–45	−1.892^a	0.059	NS
Motor or sensory weakness (stroke)
No	30 (25–60)	7–90	−1.222^a	0.222	NS
Yes	21 (20–21)	14–80	−1.222^a	0.222	NS
First presentation
Eye swelling	27.5 (23–30)	21–30	4.909^b	0.086	NS
Disturbed conscious	17 (14–20)	14–20
Facial swelling	40 (40–40)	40–40
Intranasal necrosis
No	20 (20–20)	20–20	−1.031^a	0.303	NS
Yes	30 (21–60)	7–90	−1.031^a	0.303	NS
Palatal necrosis
No	37.5 (25–82.5)	14–90	−1.133^a	0.257	NS
Yes	27.5 (21–45)	7–80	−1.133^a	0.257	NS
Ophthalmoplegia
No	30 (20–60)	7–90	−0.165^a	0.869	NS
Yes	30 (21–60)	14–80	−0.165^a	0.869	NS
Proptosis
No	42.5 (30–75)	7–90	−1.991^a	0.046	S
Yes	21 (17–27.5)	14–60	−1.991^a	0.046	S
Visual loss
No	30 (21–45)	7–90	−0.134^a	0.893	NS
Yes	30 (21–60)	14–80	−0.134^a	0.893	NS
Cavernous sinus thrombosis
No	30 (25–60)	14–90	−1.123^a	0.261	NS
Yes	21 (14–60)	7–80	−1.123^a	0.261	NS
Facial skin necrosis
No	30 (21–60)	7–90	−1.348^a	0.178	NS
Yes	14 (14–14)	14–14	−1.348^a	0.178	NS
Cranial nerves involvement
Negative	30 (21–45)	14–90	−0.128^a	0.898	NS
Facial	40.5 (14–67.5)	7–75	−0.128^a	0.898	NS

P-value > 0.05, nonsignificant; P-value < 0.05, significant; P-value < 0.01, highly significant
^aMann-Whitney test
^bKruskal-Wallis test